POZEN Logo
Print Page   Close Window

2005 Press Releases

DATETITLE 
November 28, 2005POZEN Receives Approval for MT 100 in the United KingdomPrinter Friendly Version
November 16, 2005POZEN Names Dr. Everardus Orlemans as Vice President, Clinical ResearchPrinter Friendly Version
November 14, 2005Pozen Announces Dismissal of Derivative ActionPrinter Friendly Version
November 09, 2005POZEN Names Dr. Elly Savaluny as Vice President, Biostatistics and Data ManagementPrinter Friendly Version
November 02, 2005POZEN Presents Data on PN 100 Combination Product--Designed to Help Prevent NSAID-Induced Gastric Complications; Proof-of-Concept Study Presentation at American College of Gastroenterology (ACG) Annual MeetingPrinter Friendly Version
October 27, 2005Pozen Reports Third Quarter 2005 Results; Trexima(TM) NDA Accepted for Filing by FDA in OctoberPrinter Friendly Version
October 13, 2005POZEN Announces October 27 Webcast of Third Quarter ResultsPrinter Friendly Version
October 11, 2005GlaxoSmithKline and POZEN Announce Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) New Drug Application Accepted for Review by FDAPrinter Friendly Version
September 13, 2005Pozen to Present at UBS Global Life Sciences ConferencePrinter Friendly Version
August 16, 2005POZEN Receives Patent on Novel Pain Management/GI Combination Product; Company to Present Study Data at ACG Annual Meeting in November 2005Printer Friendly Version
August 08, 2005POZEN Submits New Drug Application for Trexima(TM) (Sumatriptan Succinate and Naproxen Sodium) for the Acute Treatment of MigrainePrinter Friendly Version
August 05, 2005POZEN Provides Results of FDA Advisory Committee Meeting on MT 100(TM) (Naproxen Sodium and Metoclopramide Hydrochloride)Printer Friendly Version
July 28, 2005POZEN Reports Second Quarter 2005 Results; Trexima(TM) NDA on Track for Q3 2005 SubmissionPrinter Friendly Version
July 14, 2005POZEN Announces July 28 Webcast of Second Quarter ResultsPrinter Friendly Version
June 29, 2005FDA Sets August 4, 2005 for Advisory Committee Meeting to Consider Tardive Dyskinesia Risk with MT 100Printer Friendly Version
June 23, 2005POZEN Names Dr. William Kelce as Vice President, Pre-Clinical DevelopmentPrinter Friendly Version
June 21, 2005POZEN Names Lisa Zimmerman Vice President, Quality AssurancePrinter Friendly Version
May 25, 2005POZEN to Present at Friedman Billings Ramsey 9th Annual Growth ConferencePrinter Friendly Version
May 16, 2005POZEN to Present at UBS Global Pharmaceuticals ConferencePrinter Friendly Version
April 28, 2005POZEN Reports First Quarter 2005 Results; Trexima NDA Scheduled for 3Q 2005; Notice of Allowance Received for New Patent Application Describing Gastroprotective NSAID ProductsPrinter Friendly Version
April 21, 2005POZEN Hits All Primary Endpoints in Second Phase III Pivotal Trial for Trexima; NDA Submission Scheduled for 3Q 2005Printer Friendly Version
April 14, 2005POZEN Announces April 28 Webcast of First Quarter 2005 ResultsPrinter Friendly Version
February 28, 2005POZEN Reports Fourth Quarter and Year End 2004 Results; Completes First Trexima Phase III StudyPrinter Friendly Version
February 25, 2005Pozen to Present at Wells Fargo Securities Health Care ConferencePrinter Friendly Version
February 18, 2005POZEN Reports Fourth Quarter and Full-Year 2004 ResultsPrinter Friendly Version
February 07, 2005POZEN To Present at NCINVEST2005 Investor ConferencePrinter Friendly Version
January 26, 2005POZEN Receives Positive News on MT 100 in the U.K.Printer Friendly Version
January 25, 2005European Patent Issued to POZEN for Treatment of MigrainePrinter Friendly Version
January 20, 2005Pozen to Present at Piper Jaffray Health Care ConferencePrinter Friendly Version
January 12, 2005POZEN Inc. Adopts Stockholder Rights PlanPrinter Friendly Version